Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.01% | 246.75% | -256.98% | 50.68% | -334.38% |
| Total Depreciation and Amortization | -45.36% | -92.19% | -64.44% | -51.91% | -46.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -188.25% | 1,629.26% | 118.23% | -64.07% | 124.86% |
| Change in Net Operating Assets | 12.03% | -1,843.06% | 117.65% | -31.38% | 45.93% |
| Cash from Operations | -32.35% | 5.07% | 5.20% | 30.41% | -5.99% |
| Capital Expenditure | 89.62% | -55.49% | 370.11% | -687.95% | -318.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -105.90% | -- | -- | -- |
| Other Investing Activities | 126.04% | -82.08% | -65.32% | 103.77% | -- |
| Cash from Investing | 125.91% | -83.85% | -75.89% | 103.66% | -112,409.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 155.03% | 294.61% | 323.96% | 850.30% | 1,223.51% |
| Repurchase of Common Stock | -18.52% | 60.86% | 90.53% | 94.34% | 67.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -101.24% | -- | -- | -- |
| Cash from Financing | 3.33% | 61.18% | 220.24% | 157.38% | 71.58% |
| Foreign Exchange rate Adjustments | -61.35% | 369.12% | 140.30% | -76.09% | 129.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.46% | -107.98% | 988.44% | 99.96% | -72.32% |